Altogether, these results support the use of plasma NTA-tau as a scalable, cost-effective and non-invasive substitute of tau-PET imaging also for prognosis, but also as a surrogate marker of disease progression (as evinced by its strong association with brain atrophy and cognitive decline), which may be useful both in the clinical settings and for clinical trials. The gene discussed is MAPT; the disease is Brain atrophy.